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passing rate for target volumes was found to be above 96% 
for a 3%/3mm criteria. Differences in tumor control 
probability were within 2.5% for liver and breast, however, 
for head-and-neck and prostate patients the differences were 
up to 6.5% and up to 11% for lung patients. 
We conclude that approximations introduced in analytical 
dose calculation methods can result in significant range 
uncertainties for heterogeneous patient geometries or 
introduce a systematically reduced dose in target volumes. 
Routine MC simulations for treatment planning or verification 
may be necessary to ensure full target coverage to the 
prescribed dose levels.  In particular for clinical trials 
comparing photon vs. proton treatments, MC simulations may 
be required to avoid bias due to differences in dose 
calculations. 
   
SP-0112   
Proton beam monitor chamber calibration in clinical 
practice 
C. Gomà1 
1Swiss Federal Institute of Technology Zurich, Department of 
Physics, Zurich, Switzerland  
 
This talk describes the reference dosimetry of clinical proton 
beams. The main goal is to clarify the application of the IAEA 
TRS-398 dosimetry Code of Practice to modern proton beam 
delivery systems. A clear distinction is made between (i) 
those proton beam delivery systems that should be calibrated 
with an SOBP field, and (ii) those delivery systems that 
should be calibrated with a mono-energetic field. For these 
second type of delivery systems, a word of caution is issued 
on the use of cylindrical ionisation chambers. Contrary to the 
IAEA TRS-398 recommendations, this talk presents different 
arguments in favour of taking the effective point of 
measurement of cylindrical chambers into account when 
positioning the reference point of the chamber at the 
measurement depth. Finally, this talk also discusses the 
comparison between reference dosimetry and other 
independent dosimetry techniques, such as Faraday cup 
dosimetry and water calorimetry. 
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Myth and reality of image guidance and adaptive 
treatments in proton therapy 
M. Engelsman1 
1Delft University of Technology, Holland PTC, Delft, The 
Netherlands   
  
The finite range of protons makes the delivered dose 
distribution, particularly in case of IMPT, very sensitive to 
any uncertainty and change in patient anatomy. In the best 
case, the patient anatomy and the treatment plans are 
robust over the entire treatment course such that treatment 
adaptation is not necessary. Adaptive therapy is, however, 
not simply a buzz-word, especially not for the relatively new 
indications for proton therapy in the thoracic and pelvic 
region. Existing and new proton therapy centers are working 
towards a framework that allows them to 
1) determine which patients will benefit from a treatment 
adaptation. 
2) efficiently adapt and validate the treatment plan. 
The tools for such a framework are; volumetric image-
guidance, dose-recalculation and accumulation, and plan-
reoptimization. This presentation will discuss the needs for 
these tools, their availability and integration, and the current 
reality in plan adaptation in proton therapy. 
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Adaptive dose painting in head and neck 
J. Giralt1, A. Seoane2 
1Hospital Universitario Vall d'Hebron, Radiation Oncology, 
Barcelona, Spain 
2Hospital Universitario Vall d'Hebron, Physics, Barcelona, 
Spain  
  
The benefit of intensity-modulated radiation therapy (IMRT) 
in the treatment of head-and-neck cancer (HNC) has been 
demonstrated in numerous studies. Highly conformal 
radiation allows for a high dose to high-risk areas, whilst 
sparing adjacent organs at risk (OAR) such as the parotid 
glands. Clinical studies have shown that IMRT reduces grade-3 
xerostomia in comparison to three-dimensional conformal 
radiotherapy. The next step is to develop dose-escalation 
studies, that so called “Dose painting”. Dose-painting IMRT is 
aimed at exploiting inhomogeneous dose distributions 
adapted to tumor heterogeneity. Tumor regions of increased 
radiation resistance receive escalated dose levels, whereas 
radiation-sensitive regions receive conventional or even de-
escalated dose levels. Dose painting relies on biologic 
imaging. On the other hand, the changes to the dose 
distribution during treatment based on specific  patients 
variations due to weight loss and tumor shrink must be 
corrected. For that purpose Adaptative Radiotherapy is 
developed. This is done by means of:  
a)  Image guided RT: Repositioning of the patient at the time 
of treatment  
b)  Dose tracking: Computiong fraction dose based on daily 
cone-beam CT, accumulating dose by deformable registration 
and evaluating the accumulated dose at different organs 
c)  Replanning: Adapt the dose to a systematic volumentric 
changes and compensate for undesired dose accumulation. 
We will review the whole process and we will discuss the 
clinical data published and some of the new trials that are 
under evaluation. 
    
SP-0115   
Adaptive treatment planning in soft tissue sarcoma: Why 
and when is it necessary? 
C. Dickie1, A. Parent1, P. Chung1, C. Catton1, P. Ferguson1, J. 
Wunder1, B. O'Sullivan1 
1Princess Margaret Cancer Centre, Radiation Medicine 
Department, Toronto, Canada  
   
Radiotherapy is an integral part of soft tissue sarcoma (STS) 
multidisciplinary management, with local control in excess of 
90 % for disease arising in the extremities. 
From our recently published Phase 2 study of preoperative 
image-guided intensity modulated radiation therapy (IG-
IMRT) to reduce wound and combined modality morbidities 
in lower extremity soft tissue sarcoma (LE-STS), 
approximately 20 % of the patient population required 
replanning during their course of radiation therapy (RT) due 
to soft tissue/tumour volume changes exceeding 1 cm as 
measured on daily cone beam CT localization used for RT 
guidance.   
Previous work evaluated the dosimetric effect of tumour 
volume changes (TVC) for preoperative IMRT of LE-STS to 
determine critical indicators, as measured on daily CBCT 
localization, to motivate plan adaptation.  We found that a 1 
cm TVC deviation on CBCT imaging was a reliable threshold 
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to identify potential target underdosage for increasing target 
volumes during IMRT to consider adaptive RT.  Tumor 
shrinkage had insignificant dosimetric consequences relative 
to tumour coverage and normal tissue sparing for IMRT 
treatment in this study of 18 patients; 11 growing and 7 
shrinking.   
This lecture will focus on an adaptive study in progress at The 
Princess Margaret which is an extension of the previous study 
to compare a parallel opposed pair technique, conformal 
approach, and IMRT, for 26 patients that required plan 
adaptation for significant TVC during radiotherapy.   Target 
coverage and normal tissue sparing will be compared for the 
shrinking and growing cohorts in order to communicate 
evidence based critical indicators for adaptive IMRT, 
conformal or POP planning for STS patients.  
Adaptive issues and strategies will be discussed for LE-STS 
radiotherapy, using case examples to highlight the different 
considerations and critical thresholds for various RT 
techniques.    
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Automatic planning strategies  
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Mens1, L. Incrocci1, S. Breedveld1 
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Purpose/Objective: Treatment plans are commonly 
generated by dosimetrists in an iterative trial-and-error 
procedure, aiming at steering the TPS towards an acceptable 
solution. Plan generation may take op to several days of 
workload. Moreover, final plan quality may strongly depend 
on the skills and experience of the dosimetrist, and on 
allotted time. At Erasmus MC, systems for fully automated 
plan generation have been developed to replace the labour-
intensive and operator-dependent trial-and-error approach. 
The core of all systems is “Erasmus-iCycle” (Med Phys. 2012; 
39(2): 951), an in-house optimizer for lexicographic multi-
criterial plan generation. For prostate, head and neck, and 
cervical cancer patients treated at our linacs, automated 
planning is in full clinical use. For Cyberknife (Accuray Inc.) 
and proton therapy, experimental systems are available but 
not yet in routine use. An overview of automated plan 
generation at Erasmus MC will be provided with an accent on 
the clinical application. Applied algorithms will be briefly 
touched. The clinical use and scientific studies on the added 
value of automated planning will be discussed in detail.  
Material/methods:  For each linac patient, the IMRT or VMAT 
treatment plan is automatically generated (no human 
interference) by the clinical TPS (Monaco, Elekta AB), based 
on a patient-specific template. This template is derived 
from a treatment plan that is automatically pre-generated 
with the in-house Erasmus-iCycle optimizer. For individual 
patients of a treatment site (e.g. prostate), automatic plan 
generation in Erasmus-iCycle is based on a fixed ‘wishlist’ 
with hard constraints and treatment objectives with assigned 
priorities. These site-specific wishlists are a priori 
generated in an iterative procedure with wishlist updates in 
every iteration step, based on physicians’ evaluations of 
plans generated with the current wishlist version. In case of 
IMRT, Erasmus-iCycle can be used for integrated beam profile 
optimization and (non-coplanar) beam angle selection. 
Generated Erasmus-iCycle IMRT plans are pareto optimal. 
For Cyberknife treatment, similar systems are being 
developed for both the variable aperture collimator (IRIS) 
and the MLC, using Erasmus-iCycle pre-optimization and final 
plan generation with the clinical TPS (Multiplan, Accuray 
Inc). For intensity-modulated proton therapy (IMPT), 
Erasmus-iCycle has been extended with novel algorithms for 
fast plan generation and plan delivery, saving per patient a 
substantial amount of in-room time compared to plans 
generated with classical optimizers. Novel strategies for 
robust IMPT planning are being explored.  
Results:  In a prospective clinical H&N cancer study, treating 
radiation oncologists selected the Erasmus-iCycle/Monaco 
plan in 97% of cases rather than the plan generated with 
Monaco by trial-and-error (IJROBP 2013; 85(3): 866-72). For a 
group of 44 cervical cancer patients, dual-arc VMAT Erasmus-
iCycle/Monaco plans were superior to plans generated 
manually by an expert cervical cancer planner using Monaco, 
spending many hours; reduced small bowel V15Gy, V45Gy, and 
Dmean, bladder Dmean, and rectum Dmean, all p<0.001. For 30 
prostate cancer patients, differences between Erasmus-
iCycle/Monaco VMAT plans and manual VMAT plans, the latter 
generated by an expert planner with up to 4 hours planning 
hands-on time, were statistically insignificant (IJROBP 2014; 
88(5): 1175-9). All attempts to use automatically generated 
plans as a starting point for manual generation of further 
improved plans have been unsuccessful. 
Conclusion:  Automatic plan generation with consistent high 
plan quality and vast reductions in planning workload is 
feasible. For prostate, head and neck, and cervical cancer 
patients all clinical plans are currently automatically 
generated. For other sites (breast, lung, liver), automated 
planning is being investigated. Use of automated planning for 
Cyberknife and IPMT is being explored.  
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Differential dosing in MRI guided spinal stereotactic body 
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Purpose/Objective: Concern has been raised about the 
extreme dose-fractionation schemes and large biologically 
effective dose used in spinal SBRT because of the greater 
probability of vertebral compression fractures (VCF). 
Prevention of VCF is challenging because the metastatic 
disease lies within the segment at risk. In attempt to reduce 
the risk of VCF, we introduce ‘differential dosing’. MRI 
guidance is used to deliver a high radiation dose to the 
metastasis exclusively. Adjacent healthy appearing bone 
marrow spaces which may possibly contain subclinical disease 
receive the conventional low dose of 8 Gy. Differential dosing 
has the potential advantage of lowering the risk of VCF by 
sparing the unaffected, healthy bone tissue surrounding the 
metastasis while also treating the subclinical disease. In this 
work, the technique used to create differential dosing 
treatment plans and the accuracy of dose delivery are 
presented. 
Materials and Methods: VMAT plans were created for 10 
spinal metastatic patients using Monaco (Elekta, Sweden) 
treatment planning system. Two 10MV photon beam partial 
arcs were employed. Doses of 18 Gy to the metastasis (PTVb) 
and 8 Gy to the surrounding bony compartment (PTVe) were 
prescribed in one fraction. A maximum dose of 25.2Gy and a 
mean dose in the range 17-19Gy were allowed to PTVb. 
Treatment plans were optimized according to the following 
priority list: spinal cord dose constraint (V10<0.35cc), PTVb 
coverage, PTVb mean dose, PTVe dose gradient, PTVe 
